Scarica l'app Stockscreener
24.66
1.82%
0.44
Dopo l'orario di chiusura:
24.19
-0.47
-1.91%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$24.22
Aprire:
$23.52
Volume 24 ore:
1.85M
Relative Volume:
0.95
Capitalizzazione di mercato:
$2.51B
Reddito:
$139.74M
Utile/perdita netta:
$-79.99M
Rapporto P/E:
-24.28
EPS:
-1.0157
Flusso di cassa netto:
$-360.05M
1 W Prestazione:
+4.40%
1M Prestazione:
-14.05%
6M Prestazione:
-3.63%
1 anno Prestazione:
+33.44%
Intervallo 1D:
$23.52
$24.99
Intervallo di 1 settimana:
$21.63
$25.30
Portata 52W:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
24.66 | 2.51B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
SG Americas Securities LLC Boosts Beam Therapeutics Stake by 139% - National Today
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics Inc. (BEAM) interactive stock chart - Yahoo Finance Singapore
Beam Therapeutics (NASDAQ: BEAM) awards 20,000 RSUs to Chief Legal Officer - Stock Titan
Beam Therapeutics (BEAM) awards 20,000 RSUs to SVP Bethany Cavanagh - Stock Titan
Beam Therapeutics (BEAM) awards 31,750 RSUs to Chief Medical Officer Amy Simon - Stock Titan
CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs - Stock Titan
Beam Therapeutics (BEAM) grants president 40,000 restricted stock units - Stock Titan
Beam Therapeutics (BEAM): Among the stocks that could 10x over the next 5 years - MSN
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells 25,000 Shares of Stock - MarketBeat
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years - Yahoo Finance
Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing - Moomoo
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
BEAM.O Technical Analysis & Stock Price Forecast - intellectia.ai
Beam (BEAM) Reports Promising Data from BEACON Trial in Sickle C - GuruFocus
Beam Therapeutics publishes sickle cell therapy trial data By Investing.com - Investing.com Australia
Why Is BEAM Stock Edging Higher After Hours Today? - Stocktwits
Beam Therapeutics CEO Evans sells $1.1m in stock By Investing.com - in.investing.com
Beam Therapeutics CEO Evans sells $1.1m in stock - Investing.com
Beam Therapeutics (BEAM) CEO sells 50K shares, gains 90K RSUs - Stock Titan
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - The Manila Times
In 31 sickle cell patients, Beam saw no severe pain crises after risto-cel - Stock Titan
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
ETRADE Financial (NASDAQ: BEAM) insider sales and restricted vesting - Stock Titan
BEAM (NASDAQ: BEAM) affiliate notifies sale of 25,000 shares via option exercise - Stock Titan
Beam to advance gene-editing drug to pivotal development - MSN
BEAM (NASDAQ: BEAM) insider schedules 25,000-share sale after option exercise - Stock Titan
Beam Therapeutics gains on clinical update as gene therapy hits protective protein levels - MSN
(BEAM) Risk Channels and Responsive Allocation - Stock Traders Daily
JPMorgan Chase & Co. Has $13.14 Million Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Risk Recap: Is Beam Therapeutics Inc a cyclical or defensive stock2026 Levels & Long-Term Growth Plans - baoquankhu1.vn
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-03-27 - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Price Targets Rise As Nasdaq Futures Move - Kalkine Media
How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding - finance.yahoo.com
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF) - The Globe and Mail
Vanguard disaggregates holdings; reports 0% in Beam Therapeutics (NASDAQ: BEAM) - Stock Titan
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Sahm
Beam Therapeutics (NASDAQ:BEAM) Trading 5.5% Higher on Analyst Upgrade - MarketBeat
Analysts’ Top Healthcare Picks: Alpha Teknova (TKNO), Beam Therapeutics (BEAM) - The Globe and Mail
BEAM Eyes Global Expansion of AATD Study After Strong Early Data - The Globe and Mail
BEAM Stock Sees Price Target Raised by Citigroup Analyst | BEAM - GuruFocus
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $68.00 at Citigroup - MarketBeat
Beam Therapeutics stock holds at Outperform on AATD data - Investing.com UK
Beam Therapeutics stock holds at Outperform on AATD data By Investing.com - in.investing.com
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):